HRP20040846A2 - Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents - Google Patents

Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents Download PDF

Info

Publication number
HRP20040846A2
HRP20040846A2 HR20040846A HRP20040846A HRP20040846A2 HR P20040846 A2 HRP20040846 A2 HR P20040846A2 HR 20040846 A HR20040846 A HR 20040846A HR P20040846 A HRP20040846 A HR P20040846A HR P20040846 A2 HRP20040846 A2 HR P20040846A2
Authority
HR
Croatia
Prior art keywords
migraine
topiramate
antimigraine
treatment
day
Prior art date
Application number
HR20040846A
Other languages
English (en)
Croatian (hr)
Inventor
Ian
Original Assignee
Ortho-Mcneil Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical filed Critical Ortho-Mcneil Pharmaceutical
Publication of HRP20040846A2 publication Critical patent/HRP20040846A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20040846A 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents HRP20040846A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (1)

Publication Number Publication Date
HRP20040846A2 true HRP20040846A2 (en) 2005-06-30

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040846A HRP20040846A2 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Country Status (18)

Country Link
US (2) US20030225002A1 (https=)
EP (1) EP1478400A1 (https=)
JP (1) JP2005518439A (https=)
KR (1) KR101008326B1 (https=)
CN (1) CN100352506C (https=)
AU (1) AU2003213242A1 (https=)
BR (1) BR0307951A (https=)
CA (1) CA2419989A1 (https=)
HR (1) HRP20040846A2 (https=)
IL (2) IL163720A0 (https=)
MX (1) MXPA04008259A (https=)
NO (1) NO20043984L (https=)
NZ (1) NZ534874A (https=)
PL (1) PL372393A1 (https=)
RU (1) RU2004126093A (https=)
UA (1) UA81110C2 (https=)
WO (1) WO2003072138A1 (https=)
ZA (1) ZA200407729B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005079787A1 (en) * 2004-02-17 2005-09-01 Sepracor Inc. Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
CN101472644B (zh) * 2006-04-13 2014-04-23 纽帕特公司 递送抗偏头痛化合物的透皮方法和系统
WO2007127207A2 (en) * 2006-04-25 2007-11-08 Proethic Pharmaceuticals, Inc. Fixed combination dosage forms for the treatment of migraine
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2555066T3 (es) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
ES2645719T3 (es) * 2006-12-04 2017-12-07 Supernus Pharmaceuticals, Inc. Formulaciones de topiramato de liberación inmediata mejoradas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
EP2331100B1 (en) * 2008-09-17 2014-07-16 The McLean Hospital Corporation Methods and kits for treating cluster headache disorders
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
CA3039169A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
AU1930897A (en) * 1997-03-03 1998-09-22 Laboratoires Remilea Plant extract compositions, method of preparation, and pharmaceutical comp ositions containing them
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
ES2228465T3 (es) * 1999-01-19 2005-04-16 Ortho-Mcneil Pharmaceutical, Inc. Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes.
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use

Also Published As

Publication number Publication date
AU2003213242A1 (en) 2003-09-09
IL163720A (en) 2012-06-28
JP2005518439A (ja) 2005-06-23
KR101008326B1 (ko) 2011-01-13
KR20040091074A (ko) 2004-10-27
CN1646168A (zh) 2005-07-27
US20030225002A1 (en) 2003-12-04
WO2003072138A1 (en) 2003-09-04
RU2004126093A (ru) 2005-04-10
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
BR0307951A (pt) 2004-12-21
CN100352506C (zh) 2007-12-05
IL163720A0 (en) 2005-12-18
NZ534874A (en) 2007-03-30
EP1478400A1 (en) 2004-11-24
ZA200407729B (en) 2006-06-28
UA81110C2 (en) 2007-12-10
CA2419989A1 (en) 2003-08-05
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
MXPA04008259A (es) 2005-05-27

Similar Documents

Publication Publication Date Title
HRP20040846A2 (en) Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
Klein et al. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US6627653B2 (en) Anticonvulsant derivatives useful for the treatment of depression
EP3340971B1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
CA3076995A1 (en) Use of cannabidiol in combination with 5-ht2b receptor agonists or amphetamins in the treatment of epilepsy
US11571397B2 (en) Compositions and methods for treating seizure-induced sudden death
CA3062247A1 (en) Methods of treating doose syndrome using fenfluramine
KR20180008634A (ko) 우울증 치료를 위한 방법 및 키트
Goonawardena et al. Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat
JP2004527553A (ja) 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
Latini et al. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy
Pabis et al. Pharmacotherapy of aggressive behavior
KR20220101610A (ko) 펜플루라민을 사용하여 간질 환자를 치료하는 방법
Tracz et al. Epilepsy and Related Seizure Disorders
HK1080731B (en) Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments
CA3233107A1 (en) 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
EA044821B1 (ru) Способ увеличения биологической доступности и степени воздействия активатора потенциал-зависимых калиевых каналов
Jedsadayanmata Zonisamide: Clinical efficacy and safety in refractory partial epilepsy
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130104

Year of fee payment: 11

ODBI Application refused